
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About
Aura Biosciences Inc (AURA)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/07/2025: AURA (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -59.61% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 389.62M USD | Price to earnings Ratio - | 1Y Target Price 21.83 |
Price to earnings Ratio - | 1Y Target Price 21.83 | ||
Volume (30-day avg) 125609 | Beta 0.33 | 52 Weeks Range 6.63 - 12.38 | Updated Date 02/9/2025 |
52 Weeks Range 6.63 - 12.38 | Updated Date 02/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.73 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -30.22% | Return on Equity (TTM) -50.99% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 234328434 | Price to Sales(TTM) - |
Enterprise Value 234328434 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -5.68 | Shares Outstanding 49951500 | Shares Floating 34354121 |
Shares Outstanding 49951500 | Shares Floating 34354121 | ||
Percent Insiders 3.09 | Percent Institutions 82.84 |
AI Summary
Aura Biosciences Inc. - A Comprehensive Overview
Company Profile:
History and Background:
Aura Biosciences Inc. (AURA) is a clinical-stage biotechnology company founded in 2019. Headquartered in Cambridge, Massachusetts, AURA focuses on developing novel therapies for patients with solid tumors. The company leverages its proprietary STING agonist platform to create therapies that activate the innate immune system to fight cancer.
Core Business Areas:
STING Agonist Platform: AURA's core technology platform revolves around the development of STING (Stimulator of Interferon Genes) agonists, which are molecules that activate the innate immune system.
Therapeutic Development: AURA currently focuses on developing two clinical-stage STING agonists:
- AUNP-12: Designed as a local treatment for melanoma, AUNP-12 is currently in a Phase 1b clinical trial.
- AUNP-19: This intratumoral STING agonist is being tested in a Phase 1b clinical trial for the treatment of head and neck cancer.
Leadership Team and Corporate Structure:
- CEO: Elisabet de los Pinos
- President and Chief Medical Officer: Dr. Barbara Fox
- Chief Scientific Officer: Dr. Peter Van Vlasselaer
- AURA's leadership team comprises experienced professionals with expertise in drug development, clinical research, and finance.
Top Products and Market Share:
- AUNP-12 and AUNP-19 are currently in clinical trials and not yet commercially available. Therefore, AURA does not have any marketed products or market share data.
- AURA's STING agonist platform holds significant promise for the future development of innovative cancer therapies.
Total Addressable Market:
- The global market for cancer immunotherapy was valued at approximately $171.3 billion in 2022 and is projected to reach $314.7 billion by 2029.
- AURA's STING agonists have the potential to target a significant portion of this market, particularly in the melanoma and head and neck cancer segments.
Financial Performance:
- As a clinical-stage company, AURA does not currently generate significant revenue.
- Net income, profit margins, and EPS are also not applicable at this stage.
- AURA's financial performance is primarily driven by research and development expenses related to its clinical trials.
Dividends and Shareholder Returns:
- AURA is a pre-revenue company and does not currently pay dividends.
- Shareholder returns are primarily driven by stock price performance, which has been volatile in recent months.
Growth Trajectory:
- AURA has experienced significant growth in its clinical development activities in recent years.
- Positive data from ongoing clinical trials for AUNP-12 and AUNP-19 could fuel further growth in the future.
- AURA's future growth potential is also dependent on its ability to secure funding for further clinical development and commercialization efforts.
Market Dynamics:
- The cancer immunotherapy market is rapidly evolving, with significant investment in new technologies and clinical trials.
- AURA's STING agonists have the potential to compete with other immunotherapies, such as checkpoint inhibitors.
- AURA's success will depend on its ability to demonstrate the efficacy and safety of its STING agonists in clinical trials and differentiate itself from competitors.
Competitors:
- Major competitors in the STING agonist space include:
- Enobia Pharma (ENOB)
- ImmunoGen (IMGN)
- Oncosec Medical (ONCS)
- Mustang Bio (MBIO)
- AURA's competitive advantages include its proprietary STING agonist platform, experienced leadership team, and promising clinical data.
Potential Challenges and Opportunities:
Challenges:
- Clinical trial risks and uncertainties remain a significant challenge for AURA.
- Competition from established players in the cancer immunotherapy market is intense.
- Funding future development and commercialization efforts will be crucial for AURA's success.
Opportunities:
- Positive clinical trial results could lead to significant market opportunities for AURA.
- Partnerships with larger pharmaceutical companies could provide AURA with additional funding and expertise.
- The rapidly evolving cancer immunotherapy market presents significant opportunities for innovation and differentiation.
Recent Acquisitions:
AURA has made no acquisitions in the last three years.
AI-Based Fundamental Rating:
- Currently, AURA does not have a public AI-based rating due to its pre-revenue status and lack of sufficient data for analysis.
Sources and Disclaimers:
- Information for this analysis was gathered from sources such as Aura Biosciences' website, SEC filings, and industry reports.
- Please note that this overview is for informational purposes only and should not be considered investment advice. Investors should conduct their due diligence before making any investment decisions.
Conclusion:
Aura Biosciences is a promising clinical-stage biotechnology company with a novel STING agonist platform and a promising pipeline of cancer immunotherapy candidates. However, as a pre-revenue company, AURA faces significant risks and uncertainties. Investors should carefully consider the company's financial position, clinical development progress, competitive landscape, and potential opportunities and challenges before making any investment decisions.
About Aura Biosciences Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-10-29 | Founder, CEO, President & Director Dr. Elisabet de los Pinos Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 88 | Website https://www.aurabiosciences.com |
Full time employees 88 | Website https://www.aurabiosciences.com |
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmette"guérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.